Cogent Biosciences(COGT)
$27.74-0.07 (-0.25%)
COGT
Cogent Biosciences financials statements
$27.74
At close:-0.07 (-0.25%)
Want to see COGT full AI Analyst Report?
Cogent Biosciences (COGT) Ratios
741 Followers
Cogent Biosciences Ratios
COGT's free cash flow for Q3 2026 was $-80.89M. For the 2026 fiscal year, COGT's free cash flow was decreased by $-108.00K and operating cash flow was $-80.79M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 |
| Quick Ratio | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 |
| Cash Ratio | 4.88 | 1.76 | 1.39 | 5.21 | 12.86 |
| Solvency Ratio | -1.08 | -3.51 | -3.39 | -2.98 | -3.92 |
| Operating Cash Flow Ratio | -4.13 | -3.73 | -4.02 | -4.42 | -3.44 |
| Short-Term Operating Cash Flow Coverage | -170.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 609.12M | $ 224.86M | $ 215.14M | $ 219.89M | $ 204.72M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.27 | 0.05 | 0.06 | 0.07 | 0.01 |
| Debt-to-Equity Ratio | 0.40 | 0.07 | 0.07 | 0.08 | 0.01 |
| Debt-to-Capital Ratio | 0.28 | 0.06 | 0.07 | 0.07 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.47 | 1.28 | 1.22 | 1.18 | 1.08 |
| Debt Service Coverage Ratio | -69.71 | 0.00 | 0.00 | -35.59 | 0.00 |
| Interest Coverage Ratio | -108.87 | 0.00 | 0.00 | -37.06 | 0.00 |
| Debt to Market Cap | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.59 | 0.17 | 0.24 | 0.40 | 0.08 |
| Net Debt to EBITDA | 0.18 | 0.32 | 0.17 | 0.85 | 2.94 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.67% | 92.72% | 92.45% | 94.86% | 95.66% |
| Return on Assets (ROA) | -35.08% | -78.03% | -61.39% | -46.62% | -31.14% |
| Return on Equity (ROE) | -51.69% | -99.83% | -74.63% | -54.84% | -33.74% |
| Return on Capital Employed (ROCE) | -38.16% | -101.38% | -75.61% | -53.96% | -35.14% |
| Return on Invested Capital (ROIC) | -38.09% | -100.80% | -75.23% | -53.68% | -34.76% |
| Return on Tangible Assets | -35.08% | -78.03% | -61.39% | -46.62% | -31.14% |
| Earnings Yield | -5.75% | -31.58% | -41.08% | -20.65% | -21.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -751.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 751.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.64 | -2.00 | -1.93 | -2.02 | -1.52 |
| Free Cash Flow Per Share | -1.65 | -2.01 | -1.96 | -2.14 | -1.56 |
| Dividend Paid and CapEx Coverage Ratio | -170.17 | -362.64 | -54.94 | -17.29 | -34.18 |
| Capital Expenditure Coverage Ratio | -170.17 | -362.64 | -54.94 | -17.29 | -34.18 |
| Operating Cash Flow Coverage Ratio | -1.04 | -11.90 | -8.15 | -6.04 | -18.63 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -4.65% | -25.72% | -33.40% | -18.48% | -18.20% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -17.41 | -3.17 | -2.43 | -4.84 | -4.60 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 8.99 | 3.16 | 1.82 | 2.66 | 1.55 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -21.50 | -3.89 | -2.99 | -5.41 | -5.49 |
| Price-to-Operating Cash Flow Ratio | -21.62 | -3.90 | -3.05 | -5.72 | -5.66 |
| Price-to-Earnings Growth (PEG) Ratio | 1.44 | -1.92 | -0.34 | -0.22 | 0.07 |
| Enterprise Value Multiple | -17.61 | -2.90 | -2.12 | -3.94 | -1.57 |
| Enterprise Value | 5.66B | 729.38M | 434.01M | 558.79M | 115.78M |
| EV to EBITDA | -17.61 | -2.90 | -2.12 | -3.94 | -1.57 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -21.28 | -3.50 | -2.77 | -4.45 | -1.91 |
| EV to Operating Cash Flow | -21.40 | -3.51 | -2.83 | -4.71 | -1.97 |
| Tangible Book Value Per Share | 3.95 | 2.47 | 3.24 | 4.35 | 5.53 |
| Shareholders’ Equity Per Share | 3.95 | 2.47 | 3.24 | 4.35 | 5.53 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.04 | -2.46 | -2.42 | -2.39 | -1.87 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.00 | 0.92 | 0.95 | 0.96 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.80 | 0.81 | 0.80 | 0.85 | 0.81 |
Currency in USD

